美国FDA顾问指出,Replimune Group Inc.旗下皮肤癌药物研究的疗效数据不仅具备可评估性,而且具有显著的临床意义。这些结论标志着该药物在研发进程中迈出了关键一步。
美国FDA顾问指出,Replimune Group Inc.旗下皮肤癌药物研究的疗效数据不仅具备可评估性,而且具有显著的临床意义。这些结论标志着该药物在研发进程中迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.